Lobby organisation
European Confederation of Pharmaceutical Entrepreneurs
Business group · Health & pharma · HQ: Belgium · Transparency Register entry
As of 7 November 2026, European Confederation of Pharmaceutical Entrepreneurs appears in 50 declared MEP meetings (31 different MEPs), most often with European People's Party.
In their own words
“The European Confederation for Pharmaceutical Entrepreneurs (EUCOPE) is the voice of small to medium-sized innovative companies in the fields of pharmaceuticals, biotechnologies and medical devices. Via its member associations such as the German Pharmaceutical Industry Association (BPI), the British Ethical Medicines Industry Group (EMIG), France Biotech and the Swedish Association lif, EUCOPE represents over 2600 member companies.”
Read the rest of the statementShow less of the statement
“Corporate members include innovative family-owned companies and companies active in the field of rare diseases. EUCOPE furthers its members' scientific, technical, economic and legal objectives and represents them towards national and international governmental organisations, in particular towards the EU institutions and agencies.”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 50 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2020–2026. Bar length is relative to its busiest year (17 in 2025). Hatched: 2026 is a part-year - the record runs to 6 Nov 2026.
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 15 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 4 Sep 2026 | Marie-Sophie Christ | EU Health Policy |
| 20 Jul 2026 | Angelika Niebler | EU Pharma Policies |
| 29 Apr 2026 | Nikos Papandreou | Rare diseases |
| 29 Apr 2026 | Maria Grapini | Critical medicine |
| 28 Apr 2026 | Aurelijus Veryga | Strengthening EU Action on Rare Diseases and Life Sciences Competitiveness |
| 28 Apr 2026 | Tomislav Sokol | Health Policy |
| 28 Apr 2026 | Tilly Metz | Rare diseases |
| 28 Apr 2026 | Radan Kanev | Medicines for rare diseases |
| 28 Apr 2026 | Michalis Hadjipantela | Biotech Act |
| 28 Apr 2026 | Vytenis Povilas Andriukaitis | Biotech Act |
| 22 Apr 2026 | Wouter Beke | Biotech Act I |
| 14 Apr 2026 | Tiemo Wölken | HTA |
| 25 Mar 2026 | Oliver Schenk | Medical device regulation |
| 3 Mar 2026 | Aurelijus Veryga | Exchange of Views with the European Confederation of Pharmaceutical Entrepreneurs on the UCPM and Health Preparedness |
| 6 Nov 2025 | András Tivadar Kulja | GPL |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.